Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

141. Mortality Risks in New-Onset Childhood Epilepsy

Mortality Risks in New-Onset Childhood Epilepsy 23753097 2013 07 03 2013 09 03 2017 02 20 1098-4275 132 1 2013 Jul Pediatrics Pediatrics Mortality risks in new-onset childhood epilepsy. 124-31 10.1542/peds.2012-3998 Estimate the causes and risk of death, specifically seizure related, in children followed from onset of epilepsy and to contrast the risk of seizure-related death with other common causes of death in the population. Mortality experiences from 4 pediatric cohorts of newly diagnosed (...) patients were combined. Causes of death were classified as seizure related (including sudden unexpected death [SUDEP]), natural causes, nonnatural causes, and unknown. Of 2239 subjects followed up for >30 000 person-years, 79 died. Ten subjects with lethal neurometabolic conditions were ultimately excluded. The overall death rate (per 100 000 person-years) was 228; 743 in complicated epilepsy (with associated neurodisability or underlying brain condition) and 36 in uncomplicated epilepsy. Thirteen

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

142. Immunomodulatory interventions for focal epilepsy syndromes.

Immunomodulatory interventions for focal epilepsy syndromes. BACKGROUND: Epilepsy is a common neurological disorder made particularly disabling in the 30% of patients who do not achieve freedom from seizures despite multiple trials of antiepileptic drugs (AEDs). Experimental and clinical evidence supports a role for inflammatory pathway activation in the pathogenesis of epilepsy which, if effectively targeted by immunomodulatory interventions, highlights a potentially novel therapeutic strategy (...) . OBJECTIVES: To evaluate the efficacy and tolerability of immunomodulatory interventions as additional therapy in focal epilepsy syndromes in adults. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register (2 August 2012), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2012, Issue 7), MEDLINE (Ovid, 1946 to July week 3, 2012), the World Health Organization's International Clinical Trials Registry (2 August 2012), ClinicalTrials.gov (2 August 2012

Cochrane2013

143. Sulthiame add-on therapy for epilepsy.

Sulthiame add-on therapy for epilepsy. BACKGROUND: Epilepsy is a common neurological condition characterised by recurrent seizures. Most patients respond to conventional antiepileptic drugs, however, around 30% will continue to experience seizures despite multiple antiepileptic drugs. Sulthiame is a widely used antiepileptic drug in Europe and Israel. We present a summary of the evidence for the use of sulthiame as add-on therapy in epilepsy. OBJECTIVES: To compare the efficacy and side-effect (...) profile of sulthiame as add-on therapy compared with placebo or another antiepileptic drug. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and the WHO IRCTRP Search Portal on 28th August 2012. No language restrictions were imposed. We contacted the manufacturers of sulthiame and researchers in the field to seek any ongoing or unpublished studies. SELECTION CRITERIA: Randomised placebo-controlled add

Cochrane2013

144. [Effectiveness and safety of progabide for refractory epilepsy: a meta-analysis]

[Effectiveness and safety of progabide for refractory epilepsy: a meta-analysis] Effectiveness and safety of progabide for refractory epilepsy: a meta-analysis Effectiveness and safety of progabide for refractory epilepsy: a meta-analysis Yuan TT, Wu B, Zou XY Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Yuan TT, Wu B, Zou XY. Effectiveness and safety of progabide for refractory epilepsy: a meta-analysis. Chinese Journal (...) of Evidence-Based Medicine 2012; 12(7): 810-816 Original Paper URL Indexing Status Subject indexing assigned by CRD MeSH Epilepsy; Humans; Meta-Analysis; gamma-Aminobutyric Acid /analogs and derivatives AccessionNumber 12012038005 Date bibliographic record published 10/05/2013 Date abstract record published 08/02/2013 Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright © 2017 University of York Homepage Options Print PubMed record Original

DARE.2013

145. Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures

Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Perampanel (Fycompa - Eisai Ltd (...) .) indication: epilepsy, partial-onset seizures. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that perampanel be listed as an adjunctive therapy in the management of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy, if the following clinical criteria and condition are met: 1.Patients are currently receiving two

Health Technology Assessment (HTA) Database.2013

146. Can an epilepsy nurse specialist-led self-management intervention reduce attendance at emergency departments and promote well-being for people with severe epilepsy? A non-randomised trial with a nested qualitative phase

Can an epilepsy nurse specialist-led self-management intervention reduce attendance at emergency departments and promote well-being for people with severe epilepsy? A non-randomised trial with a nested qualitative phase Can an epilepsy nurse specialist-led self-management intervention reduce attendance at emergency departments and promote well-being for people with severe epilepsy? A non-randomised trial with a nested qualitative phase Can an epilepsy nurse specialist-led self-management (...) intervention reduce attendance at emergency departments and promote well-being for people with severe epilepsy? A non-randomised trial with a nested qualitative phase Ridsdale L, McCrone P, Morgan M, Goldstein L, Seed P, Noble A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ridsdale L, McCrone P, Morgan M, Goldstein L, Seed P, Noble A. Can

Health Technology Assessment (HTA) Database.2013

148. Aptiom (eslicarbazepine acetate) - As an add-on medication to treat seizures associated with epilepsy

Aptiom (eslicarbazepine acetate) - As an add-on medication to treat seizures associated with epilepsy Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Aptiom (Eslicarbazepine Acetate) Tablets Company: Sunovion Inc. Application No.: 022416 Approval Date: 11/08/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

149. Namyang Ketonia - ketogenic diet treatment for epilepsy

Namyang Ketonia - ketogenic diet treatment for epilepsy Namyang Ketonia – ketogenic diet treatment for epilepsy Namyang Ketonia – ketogenic diet treatment for epilepsy Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Malaysian Health Technology Assessment (MaHTAS). Namyang Ketonia – ketogenic (...) diet treatment for epilepsy. Putrajaya: Malaysian Health Technology Assessment (MaHTAS). 2013 Authors' objectives To review evidence on the effectiveness, safety and cost-effectiveness of Namyang Ketonia as a ketogenic diet treatment for epilepsy in infant and young children. Authors' conclusions There was limited but good level of retrievable evidence on the effectiveness of Namyang Ketonia as a ketogenic diet treatment for epilepsy in infant and young children. All studies seemed to show more

Health Technology Assessment (HTA) Database.2013

152. Vagus nerve stimulation for the treatment of epilepsy

Vagus nerve stimulation for the treatment of epilepsy Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share October 15, 2013 ; 81 (16) Special Article Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy Report of the Guideline Development Subcommittee (...) of the American Academy of Neurology George L. Morris , David Gloss , Jeffrey Buchhalter , Kenneth J. Mack , Katherine Nickels and Cynthia Harden First published August 28, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a393d1 George L. Morris From the Aurora Epilepsy Center (G.L.M.), St. Luke's Medical Center, Milwaukee, WI; Barrow Neurologic Institute (D.G.), Phoenix, AZ; University of Calgary (J.B.), Canada; Mayo Clinic (K.J.M., K.N.), Rochester, MN; and Hofstra University North Shore–Long Island Jewish

American Academy of Neurology2013

153. Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery

Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R Citation Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R. Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery. Toronto: Medical Advisory (...) Secretariat (MAS). Volume 12(18). 2012 Authors' conclusions Epilepsy surgery for medically intractable epilepsy in suitable candidates has consistently been found to provide favourable clinical outcomes and has been demonstrated to be cost-effective in both adult and child patient populations. The first step to increasing access to epilepsy surgery is to provide access to evidence-based care for all patients with epilepsy, both adults and children, through the provision of resources to expand EMU bed

Health Technology Assessment (HTA) Database.2012

154. Zonisamide (Zonegran) - monotherapy for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy

Zonisamide (Zonegran) - monotherapy for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy Published 08 October 2012 Statement of Advice zonisamide (Zonegran ®) 25, 50, 100mg Hard Capsules (No: 817/12) Eisai Ltd 7 September 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation zonisamide (Zonegran ®) is not recommended for use within NHS Scotland. Indication under review: monotherapy (...) for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform

Scottish Medicines Consortium2012

155. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model

The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model Journals Library An error has occurred in processing the XML

NIHR HTA programme2012

156. Epilepsy surgery: an evidence summary

Epilepsy surgery: an evidence summary Epilepsy surgery: an evidence summary Epilepsy surgery: an evidence summary Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Epilepsy surgery: an evidence summary. Toronto: Medical Advisory Secretariat (MAS). Volume 12(17). 2012 Authors' objectives (...) The objective of this analysis was to review the effectiveness of epilepsy surgery at reducing seizure frequency, as well as the safety of epilepsy surgery. Authors' conclusions There is high quality evidence that epilepsy surgery is effective at reducing seizure frequency. Two randomized controlled trials compared surgery to no surgery in patients with drug-refractory epilepsy. Both demonstrated significant reductions in seizure frequency. There are some complications associated with epilepsy surgery

Health Technology Assessment (HTA) Database.2012

157. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan.

Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Epilepsy is a common neurological disorder that is complicated by psychiatric, cognitive, and social comorbidities that have become a major target of concern and investigation in view of their adverse effect on the course and quality of life. In this report we define the specific psychiatric, cognitive, and social comorbidities of paediatric and adult epilepsy, their epidemiology, and real life effects; examine (...) the relation between epilepsy syndromes and the risk of neurobehavioural comorbidities; address the lifespan effect of epilepsy on brain neurodevelopment and brain ageing and the risk of neurobehavioural comorbidities; consider the overarching effect of broader brain disorders on both epilepsy and neurobehavioural comorbidities; examine directions of causality and the contribution of selected epilepsy-related characteristics; and outline clinic-friendly screening approaches for these problems

Lancet2012 Full Text: Link to full Text with Trip Pro

158. Epilepsy in poor regions of the world.

Epilepsy in poor regions of the world. Epilepsy is a common disorder, particularly in poor areas of the world, and can have a devastating effect on people with the disorder and their families. The burden of epilepsy in low-income countries is more than twice that found in high-income countries, probably because the incidence of risk factors is higher. Many of these risk factors can be prevented with inexpensive interventions, but there are only a few studies that have assessed the effect (...) of reducing risk factors on the burden of epilepsy. The mortality associated with epilepsy in low-income countries is substantially higher than in less impoverished countries and most deaths seem to be related to untreated epilepsy (eg, as a result of falls or status epilepticus), but the risk factors for death have not been adequately examined. Epilepsy is associated with substantial stigma in low-income countries, which acts as a barrier to patients accessing biomedical treatment and becoming integrated

Lancet2012